Skip to main content

Table 4 Results of meta-regression analyses for adverse events in liver cancer treatment with camrelizumab in combination with apatinib

From: Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of liver cancer: a systematic review and single-arm meta-analysis

Outcome

Study

Factor

Heterogeneity

P

SE

P

I2(%)

AEs (any grade)

6

Study Type

0.000

92.8

0.939

-0.0281683 to 0.0304537

AEs(grade ≥ 3)

6

Study Type

0.000

97.7

0.229

-0.2439073 to 1.020582

  1. AEs (any grade), any treatment-related adverse event (grade 1–2); AEs(grade ≥ 3), any treatment-related adverse event (grade 3–5)
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us